we recently compiled a list of the 10 Most Undervalued Quality Stocks To Buy According To Analysts. In this article, we will look at where Alkermes (NASDAQ:ALKS) ranks among the most undervalued ...

EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.

But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our ...

Alkermes plc (NASDAQ:ALKS) just released its annual report and things are looking bullish. It was overall a positive result, with revenues beating expectations by 3.4% to hit US$1.6b.

The stock price of Alkermes, a biopharmaceutical company focused on neuroscience and oncology, has seen a rise of around 16% over the last twenty-one trading days, and it is up a solid 91% over ...

View the latest Alkermes PLC (ALKS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Alkermes Price Performance. Spin-Off Research. Post-spin-off, Alkermes (RemainCo) will retain its focus on significant unmet needs within neuroscience and driving the growth of its proprietary ...

Alkermes expects that revenue for full-year 2021 will be between $1.1 billion and $1.17 billion. It anticipates GAAP loss per share of $0.53 to $0.78, with adjusted non-GAAP EPS between $0.37 and ...

Alkermes reported slightly weaker-than-expected Q1 results several weeks ago, and the stock quote is down close to -30% since February. The good news for investors is the company: (1) ...